Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

updated COVID-19 vaccine

- PMLiVE

Invivyd working with FDA towards potential Biologics License Application for COVID-19

The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment

- PMLiVE

FDA approves Pfizer and BioNTech’s jab for COVID-19

Globally, five billion doses of the companies’ vaccine have been distributed

- PMLiVE

Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

- PMLiVE

Moderna shares positive phase 3 results for mRNA flu vaccine candidate

More than 600,000 people in the US were hospitalised due to flu-related illness last year

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

The vaccine is already approved in the US for use in adults aged 60 years and older

- PMLiVE

Merck’s RSV monoclonal antibody Enflonsia approved by FDA to protect infants

Enflonsia is now the first RSV preventive for infants that can be given at the same dose regardless of weight

- PMLiVE

Pfizer’s RSV vaccine receives EC approval for individuals aged 18 to 59 years

Abrysvo is now the first RSV vaccine in the EU for non-pregnant adults in this age group

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults

RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older

- PMLiVE

EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive

Kostaive is designed to instruct the body to make more mRNA to boost immune response

- PMLiVE

WHO urges US to ‘reconsider’ withdrawal from global health organisation

President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises

- PMLiVE

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

Merck and Ridgeback initiate phase 3 study of COVID-19 oral antiviral in high-risk adults

Lagevrio is already available in the US under emergency use authorisation to treat certain cases of COVID-19

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links